Sanofi and Regeneron have filed a motion with the Federal Circuit Court of Appeals to stay (suspend) the injunction pending the appeal, and requested expedited consideration of our appeal by the Federal Circuit. We are hopeful that the appellate court will rule on our stay motion within the next few weeks. An injunction would not be in the best interests of patients, and we are focused on ensuring Praluent remains available to patients in need. It is our longstanding position that Amgen’s asserted patent claims are invalid.